Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model
A limitation for recombinant adeno-associated virus (rAAV)-mediated gene transfer into the central nervous system (CNS) is the low penetration of vectors across the human blood-brain barrier (BBB). High doses of intravenously delivered vector are required to reach the CNS, which has resulted in vary...
Main Authors: | Ren Song, Katja Pekrun, Themasap A. Khan, Feijie Zhang, Sergiu P. Paşca, Mark A. Kay |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050122001279 |
Similar Items
-
AAV Engineering for Improving Tropism to the Central Nervous System
by: Muhammad S. Ghauri, et al.
Published: (2023-01-01) -
A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells
by: Nicole L. Stone, et al.
Published: (2019-06-01) -
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
by: Marika Marino, et al.
Published: (2022-04-01) -
An Improved In Vitro Blood-Brain Barrier Model for the Evaluation of Drug Permeability Using Transwell with Shear Stress
by: Junhyeong Kim, et al.
Published: (2023-12-01) -
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
by: Marshall S. Goodwin, et al.
Published: (2020-03-01)